Research programme: cancer therapeutics- Black Belt TX/Praxis Biotech
Latest Information Update: 28 Dec 2023
At a glance
- Originator Black Belt Therapeutics; Praxis Biotech
- Developer Black Belt Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for research development in Cancer in United Kingdom
- 28 Dec 2023 No recent reports of development identified for research development in Cancer in USA
- 05 Nov 2019 Black Belt entered into research and development agreement with Praxis Biotech to jointly discover and develop cancer therapeutics in Cancer